Nanoscale radiotherapy with hafnium oxide nanoparticles
…, A Pottier, E Deutsch, J Bourhis, E Borghi… - Future …, 2012 - Future Medicine
Aim: There is considerable interest in approaches that could improve the therapeutic window
of radiotherapy. In this study, hafnium oxide nanoparticles were designed that concentrate …
of radiotherapy. In this study, hafnium oxide nanoparticles were designed that concentrate …
First-in-human study testing a new radioenhancer using nanoparticles (NBTXR3) activated by radiation therapy in patients with locally advanced soft tissue sarcomas
…, N Lassau, R Ait Sarkouh, M Dimitriu, E Borghi… - Clinical Cancer …, 2017 - AACR
Purpose: This phase I study aimed to determine the recommended dose (RD), safety profile,
and feasibility of a procedure combining intratumoral injection of hafnium oxide …
and feasibility of a procedure combining intratumoral injection of hafnium oxide …
Overview of the main methods used to combine proteins with nanosystems: absorption, bioconjugation, and encapsulation
The latest development of protein engineering allows the production of proteins having desired
properties and large potential markets, but the clinical advances of therapeutical proteins …
properties and large potential markets, but the clinical advances of therapeutical proteins …
[HTML][HTML] Hafnium oxide nanoparticles: toward an in vitropredictive biological effect?
J Marill, NM Anesary, P Zhang, S Vivet, E Borghi… - Radiation …, 2014 - Springer
Background Hafnium oxide, NBTXR3 nanoparticles were designed for high dose energy
deposition within cancer cells when exposed to ionizing radiation. The purpose of this study …
deposition within cancer cells when exposed to ionizing radiation. The purpose of this study …
New use of metals as nanosized radioenhancers
A Pottier, E Borghi, L Levy - Anticancer Research, 2014 - ar.iiarjournals.org
Since the discovery of cisplatin about 40 years ago, the design of innovative metal-based
anticancer drugs is a growing area of research. Transition metal coordination complexes offer …
anticancer drugs is a growing area of research. Transition metal coordination complexes offer …
Pp IX Silica Nanoparticles Demonstrate Differential Interactions with In Vitro Tumor Cell Lines and In Vivo Mouse Models of Human Cancers
…, J Honnorat, A Duval, A Pottier, E Borghi… - Photochemistry and …, 2010 - Wiley Online Library
Protoporphyrin IX (Pp IX) silica nanoparticles, developed for effective use in photodynamic
therapy (PDT), were explored in in vitro and in vivo models with the ambition to improve …
therapy (PDT), were explored in in vitro and in vivo models with the ambition to improve …
The future of nanosized radiation enhancers
A Pottier, E Borghi, L Levy - The British journal of radiology, 2015 - academic.oup.com
Radiotherapy has a universal and predictable mode of action, that is, a physical mode of
action consisting of the deposit of a dose of energy in tissues. Tumour cell damage is …
action consisting of the deposit of a dose of energy in tissues. Tumour cell damage is …
Metals as radio-enhancers in oncology: The industry perspective
A Pottier, E Borghi, L Levy - Biochemical and Biophysical Research …, 2015 - Elsevier
Radio-enhancers, metal-based nanosized agents, could play a key role in oncology. They
may unlock the potential of radiotherapy by enhancing the radiation dose deposit within …
may unlock the potential of radiotherapy by enhancing the radiation dose deposit within …
Phase I study of NBTXR3 nanoparticles, in patients with advanced soft tissue sarcoma (STS).
…, N Lezghed, F Azzouz, A Goberna, L Levy, B Elsa… - 2014 - ascopubs.org
10563 Background: Functionalized hafnium oxide nanoparticles (NBTXR3) have been
developed as selective radioenhancers, which may represent a breakthrough approach for the …
developed as selective radioenhancers, which may represent a breakthrough approach for the …
Mosaic trisomy 9 and lobar holoprosencephaly
…, C Danan, M Sinico, F Lelong, E Borghi… - American journal of …, 2002 - Wiley Online Library
The main features of trisomy 9 syndrome in mosaic and non‐mosaic forms have been thoroughly
described. Characteristic traits are low‐set malformed ears, micrognathia, broad nose …
described. Characteristic traits are low‐set malformed ears, micrognathia, broad nose …